Literature DB >> 10595921

Familial encephalopathy with neuroserpin inclusion bodies.

R L Davis1, P D Holohan, A E Shrimpton, A H Tatum, J Daucher, G H Collins, R Todd, C Bradshaw, P Kent, D Feiglin, A Rosenbaum, M S Yerby, C M Shaw, F Lacbawan, D A Lawrence.   

Abstract

We report on a new familial neurodegenerative disease with associated dementia that has presented clinically in the fifth decade, in both genders, and in each of several generations of a large family from New York State-a pattern of inheritance consistent with an autosomal dominant mode of transmission. A key pathological finding is the presence of neuronal inclusion bodies distributed throughout the gray matter of the cerebral cortex and in certain subcortical nuclei. These inclusions are distinct from any described previously and henceforth are identified as Collins bodies. The Collins bodies can be isolated by simple biochemical procedures and have a surprisingly simple composition; neuroserpin (a serine protease inhibitor) is their predominant component. An affinity-purified antibody against neuroserpin specifically labels the Collins bodies, confirming their chemical composition. Therefore, we propose a new disease entity-familial encephalopathy with neuroserpin inclusion bodies (FENIB). The conclusion that FENIB is a previously unrecognized neurodegenerative disease is supported by finding Collins bodies in a small kindred from Oregon with familial dementia who are unrelated to the New York family. The autosomal dominant inheritance strongly suggests that FENIB is caused by mutations in the neuroserpin gene, resulting in intracellular accumulation of the mutant protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595921      PMCID: PMC3277299          DOI: 10.1016/S0002-9440(10)65510-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Atypical myoclonus body epilepsy (adult variant).

Authors:  C L Dolman
Journal:  Acta Neuropathol       Date:  1975       Impact factor: 17.088

3.  Dimedone as an aldehyde blocking reagent to facilitate the histochemical demonstration of glycogen.

Authors:  D BULMER
Journal:  Stain Technol       Date:  1959-03

4.  Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.

Authors:  G Lennox; J Lowe; M Landon; E J Byrne; R J Mayer; R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

Review 5.  The role of thrombin-like (serine) proteases in the development, plasticity and pathology of the nervous system.

Authors:  V L Turgeon; L J Houenou
Journal:  Brain Res Brain Res Rev       Date:  1997-09-30

6.  A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing.

Authors:  Y Robitaille; S Carpenter; G Karpati; S D DiMauro
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

7.  Atypical inclusion bodies with myoclonic epilepsy.

Authors:  D K Dastur; B S Singhal; M Gootz; F Seitelberger
Journal:  Acta Neuropathol       Date:  1966-09-01       Impact factor: 17.088

8.  New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies.

Authors:  P N Leigh; A Probst; G E Dale; D P Power; J P Brion; A Dodson; B H Anderton
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 9.  Neurogenetic diseases: molecular diagnosis and therapeutic approaches.

Authors:  U Muller; M B Graeber
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

Review 10.  Genetic neurodegenerative diseases: the human illness and transgenic models.

Authors:  D L Price; S S Sisodia; D R Borchelt
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

View more
  28 in total

1.  Defining neurodegenerative diseases.

Authors:  Adrian Williams
Journal:  BMJ       Date:  2002-06-22

2.  Accumulation of mutant neuroserpin precedes development of clinical symptoms in familial encephalopathy with neuroserpin inclusion bodies.

Authors:  Giovanna Galliciotti; Markus Glatzel; Jochen Kinter; Serguei V Kozlov; Paolo Cinelli; Thomas Rülicke; Peter Sonderegger
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

Review 3.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

4.  Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin.

Authors:  Shoji Ishigami; Maria Sandkvist; Foon Tsui; Elizabeth Moore; Timothy A Coleman; Daniel A Lawrence
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

5.  The aggregation-prone intracellular serpin SRP-2 fails to transit the ER in Caenorhabditis elegans.

Authors:  Richard M Silverman; Erin E Cummings; Linda P O'Reilly; Mark T Miedel; Gary A Silverman; Cliff J Luke; David H Perlmutter; Stephen C Pak
Journal:  Genetics       Date:  2015-03-18       Impact factor: 4.562

6.  pH-dependent stability of neuroserpin is mediated by histidines 119 and 138; implications for the control of beta-sheet A and polymerization.

Authors:  Didier Belorgey; Peter Hägglöf; Maki Onda; David A Lomas
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725

7.  Generalization of variants identified by genome-wide association studies for electrocardiographic traits in African Americans.

Authors:  Janina M Jeff; Marylyn D Ritchie; Joshua C Denny; Abel N Kho; Andrea H Ramirez; David Crosslin; Loren Armstrong; Melissa A Basford; Wendy A Wolf; Jennifer A Pacheco; Rex L Chisholm; Dan M Roden; M Geoffrey Hayes; Dana C Crawford
Journal:  Ann Hum Genet       Date:  2013-03-28       Impact factor: 1.670

8.  Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.

Authors:  Manuel Yepes; Maria Sandkvist; Timothy A Coleman; Elizabeth Moore; Jiang-Young Wu; David Mitola; Thomas H Bugge; Daniel A Lawrence
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

9.  Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia.

Authors:  Marquis P Vawter; Cynthia Shannon Weickert; Erick Ferran; Mitsuyuki Matsumoto; Kevin Overman; Thomas M Hyde; Daniel R Weinberger; William E Bunney; Joel E Kleinman
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.